Clinical trials: Pneumococcal Infection
Pneumococcal Disease, Invasive
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
The goal of this clinical trial is to evaluate the immunogenicity and safety of a novel 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13-TT) as compared to Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13)…
- Trial name
- NCT05934890
- Testing
- Walvax PCV13-TT, Pfizer PCV13
- Where
- 2 sites in Indonesia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Infections, Streptococcal, Streptococcus Pneumoniae
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of…
- Trial name
- NCT00814710
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Tritanrix-HepB/Hib, Hiberix
- Where
- 4 sites in India
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
The goal of this clinical trial is to learn if whole-cell Streptococcus pneumoniae (wSp) vaccination is safe and tolerated in healthy adults. The main aim is to evaluate the safety and tolerability of wSp vaccine.
- Trial name
- STREPTO VAC I (NCT07059182)
- Testing
- Inactivated whole-cell Streptococcus pneumoniae vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
Pneumococcal Disease
Child Pneumococcal Serotype Epidemiology In Greece
Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide.
- Trial name
- NCT01111214
- Testing
- no intervention
- Where
- 9 sites in Greece
- Volunteers
- 457 people
- Sponsor
- Pfizer
Pneumococcal Infections, Streptococcal Infections
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT04841369
- Testing
- 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 3,420 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Streptococcus Pneumoniae Infection
Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.
In France, Streptococcus pneumoniae is the leading agent bacterial involved in community lung disease and meningitis. The frequency of these infections and their mortality increase significantly in those at risk such as patients…
- Trial name
- OPTIVACC (NCT05060146)
- Testing
- Structured medico-pharmaceutical collaboration
- Where
- 9 sites in France
- Volunteers
- 646 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Pneumococcal Infection
Pneumonia Vaccine in Aging HIV Positive Individuals
The investigators hypothesized that vaccination with either the 23-valent pneumococcal polysaccharide vaccine (PPV23) alone or the 13-valent pneumococcal conjugate vaccine (PCV 13) followed by PPV23 results in similar antibody…
- Trial name
- NCT02558751
- Testing
- 23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Prophylactic Pneumococcal Diseases
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .
- Trial name
- NCT00327522
- Testing
- pneumococcal vaccine
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India
The purpose of this study is to describe the safety of the study vaccine (called 13vPnC) in people who are 18-49 years of age in India.
- Trial name
- NCT05329259
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 5 sites in India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Vaccines, HIV
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent…
- Conditions
- Pneumococcal Vaccines, HIV, HIV Infections
- Trial name
- NCT00999739
- Testing
- Prevenar and Pneumo23
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Hospital Universitari Son Dureta
Pneumococcal Infections, Streptococcal Infections
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control…
- Conditions
- Pneumococcal Infections, Streptococcal Infections, Bacterial Infections
- Trial name
- NCT07017777
- Testing
- PCV13i, Prevnar 13
- Where
- 3 sites in Thailand
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Streptococcus Pneumoniae Pneumonia, Streptococcus Pneumoniae Infection
Pneumococcal Nasopharyngeal Colonization as Predictor of Community-Acquired Pneumonia (CAP) in Adults With Chronic Diseases.
Streptococcus pneumoniae (pneumococcus) is a commensal bacterium, often isolated in the nasopharynx of preschool children and older adults with weakened immune systems, a pathogen that remains the leading cause of…
- Conditions
- Streptococcus Pneumoniae Pneumonia, Streptococcus Pneumoniae Infection, Streptococcus Pneumoniae Infection Invasive, Community-acquired Pneumonia
- Trial name
- CAP (NCT04944719)
- Testing
- nasopharyngeal aspirate
- Where
- Colombia
- Volunteers
- 810 people
- Sponsor
- Universidad de la Sabana
Meningitis, Septicaemia
Understanding Pneumococcal Carriage and Disease
Pneumococcus is a bacteria that causes disease of the respiratory tract (pneumonia and middle ear infections), blood poisoning, and meningitis. It is frequently carried by people in back of the throat without symptoms.
- Conditions
- Meningitis, Septicaemia, Pneumonia
- Trial name
- NCT01996007
- Where
- United Kingdom
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pneumococcal Infections, Pneumonia, Pneumococcal
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114.
- Trial name
- PNEU-TRUE (NCT03950856)
- Testing
- V114, Prevnar 13™
- Where
- 55 sites in United States, Australia and 4 more
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
- Trial name
- NCT03835975
- Testing
- 13vPnC, PPSV23, 20vPnC
- Where
- 42 sites in United States, Sweden
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Bacterial, Healthy Volunteers
A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1.
- Conditions
- Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
- Trial name
- NCT03803202
- Testing
- ASP3772, PCV13, PPSV23
- Where
- 26 sites in United States
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Aging
Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines
This is a prospective, single-site, randomized, then open-label study designed to develop a detailed transcriptional and epigenetic profile of the immune response to pneumococcal vaccination with conjugated and non-conjugated…
- Trial name
- NCT03104075
- Testing
- Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Jackson Laboratory
Streptococcus Pneumoniae Infection, Legionella Pneumophila Serogroup 1 Infection
Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol
Beta trial to evaluate the preliminary clinical performance of the Curian S. pneumo/Legionella assay for its use in the qualitative detection of Streptococcus pneumoniae and/or Legionella pneumophila serogroup 1 antigens in human…
- Trial name
- NCT05681156
- Testing
- N/A- There is no intervention.
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Meridian Bioscience, Inc.
Infections, Streptococcal
Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals' pneumococcal vaccine (2830929A and 2830930A) administered as 3-dose primary vaccination during the first…
- Trial name
- NCT01616459
- Testing
- Pneumococcal conjugate vaccine GSK2830929A, Pneumococcal conjugate vaccine GSK2830930A, Synflorix™
- Where
- 42 sites in Czechia, Germany and 2 more
- Volunteers
- 953 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia, Streptococcus Pneumoniae Infection
Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of…
- Trial name
- NCT03696303
- Testing
- Urinary antigen detection assay
- Where
- 3 sites in Guatemala
- Volunteers
- 959 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver